Carleen Cullinane

6PUBLICATIONS
32CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 02, 2022
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.

Lorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt

|Nov 11, 2020
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.

Shunfei Yan, Jiachen Xuan, Natalie Brajanovski

|Sep 18, 2020
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.

Eric P Kusnadi, Anna S Trigos, Carleen Cullinane

|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

Elaine Sanij, Katherine M Hannan, Jiachen Xuan

|Aug 23, 2019
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.

Nicholas A Zia, Carleen Cullinane, Jessica K Van Zuylekom

|Mar 28, 2018
Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Helen B Pearson, Jason Li, Valerie S Meniel

Pageof 1

Frequent Collaborators

4 joint publications

Richard B Pearson

3 joint publications

Karen E Sheppard

3 joint publications

Keefe T Chan

3 joint publications

Anna Trigos